Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Gynecologic 2Genitourinary 2Head & Neck 1Gastrointestinal 1

Conditions

Salivary Gland Neoplasms 1

Interventions

Cisplatin 416Radiotherapy 240Radiotherapy, Intensity-Modulated 178Cetuximab 177Docetaxel 166pembrolizumab 148Carboplatin 121Fluorouracil 113Paclitaxel 90Nivolumab 82Gemcitabine 82Radiation 72Surveys and Questionnaires 71Drug Therapy 70toripalimab 68Surgical Procedures, Operative 64Magnetic Resonance Spectroscopy 63Capecitabine 50Blood Specimen Collection 50Chemoradiotherapy 46Biopsy 44camrelizumab 41durvalumab 40Radiosurgery 40Standard of Care 38Erlotinib Hydrochloride 34nimotuzumab 32130-nm albumin-bound paclitaxel 32tislelizumab 31apatinib 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × RC48 antibody × Head & Neck × Clear all
NCT05898373 2023-06-12

Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC

Peking Union Medical College

Phase 1/2 Not yet recruiting
120 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡